Efficacy and safety of vaccination of marrow transplant recipients with a live attenuated measles, mumps, and rubella vaccine.
Long-term immunity to measles, mumps, and rubella viruses was studied in 57 patients after allogeneic bone marrow transplantation. Among patients who were seropositive at the time of transplant, 51% had retained antibodies to measles, 42% had retained antibodies to mumps, and 76% had retained antibodies to rubella 2 y later. There was no difference in the ability to retain antibodies to these viruses between patients with and those without chronic graft-versus-host disease (GVHD). Twenty seronegative patients without active chronic GVHD or ongoing immunosuppressive treatment were vaccinated with a live attenuated trivalent vaccine against measles, mumps, and rubella. No early or late side effects were detected after the vaccinations. The percentages of patients who seroconverted after vaccination were 77%, 64%, and 75% for measles, mumps, and rubella, respectively. Vaccination of transplant recipients with a live attenuated vaccine against measles, mumps, and rubella is safe and usually effective 2 y after transplant if the patients do not have active chronic GVHD or ongoing immunosuppressive treatment at the time of vaccination.
Ljungman
P
P
Department of Medicine, Karolinska Institute, Huddinge Hospital, Sweden.
Fridell
E
E
Lönnqvist
B
B
Bolme
P
P
Böttiger
M
M
Gahrton
G
G
Linde
A
A
Ringdén
O
O
Wahren
B
B
D000293:Adolescent; D000328:Adult; D000914:Antibodies, Viral / Q000096:biosynthesis; D016026:Bone Marrow Transplantation; D002648:Child; D002675:Child, Preschool; D004338:Drug Combinations / Q000009:adverse effects / Q000276:immunology; D006086:Graft vs Host Disease / Q000276:immunology; D006801:Humans; D007165:Immunosuppression Therapy; D007223:Infant; D008457:Measles / Q000276:immunology*; D008458:Measles Vaccine / Q000009:adverse effects / Q000276:immunology*; D008459:Measles virus / Q000276:immunology; D022542:Measles-Mumps-Rubella Vaccine; D008875:Middle Aged; D009107:Mumps / Q000276:immunology*; D009108:Mumps Vaccine / Q000009:adverse effects / Q000276:immunology*; D009109:Mumps virus / Q000276:immunology; D012409:Rubella / Q000276:immunology*; D012411:Rubella Vaccine / Q000009:adverse effects / Q000276:immunology*; D012412:Rubella virus / Q000276:immunology; D014613:Vaccines, Attenuated / Q000009:adverse effects / Q000276:immunology
D000914:Antibodies, Viral; D004338:Drug Combinations; D008458:Measles Vaccine; D022542:Measles-Mumps-Rubella Vaccine; D009108:Mumps Vaccine; D012411:Rubella Vaccine; D014613:Vaccines, Attenuated; C040901:rubella antibodies